CMG-DIGITAL
25.4.2022 01:02:06 CEST | Business Wire | Press release
Global digital design and smart production agency CMG Digital is today relaunching as part of an ongoing evolution of its company brand.
The agency, based in Croatia, with a presence in the UK and the US, now has a new vision and is dedicating itself to putting humanity back into digital.
The acceleration of digital adoption during the pandemic brought many positives to the digital space, including investment, faster development, new services and virtual worlds. At the same time, it has also tackled issues around security, privacy, sustainability and inefficiencies.
More significantly, the acceleration of digital has seen a move towards automation and away from humanisation in digital.
The relaunched CMG Digital is the answer: an agency dedicated to supporting clients to ensure they can maximise success in digital within this context.
The new vision will also be accompanied by a new look. With the agency debuting a new logo, theme and tone of voice. The updated visual identity will represent the evolved brand values.
Putting humanity at the core of its company was an easy decision for the agency, which boasts two thirds of women holding the top management positions as well as women making up more than 55% of the overall employees. CMG Digital also boasts a mental health program called MindGiving to support the team: this includes yoga classes, managing stress workshops, meeting limits, no meeting Friday as well as additional health insurance.
Explaining the new vision, Ana Tolić, President of CMG said:
“We are both delighted and excited to enter this new era of CMG Digital history and focus on our mission of putting humanity back into digital.
“Over the course of the pandemic the lightning-fast adoption of digital meant the space quickly became inhuman and cold.
“We are an agency that recognises that we can’t replace the people's side of things with a platform, and that relationships are critical to success. We believe in focusing on B2H – Business to Human.”
The relaunch will also keep digital sustainability at the heart of the agency.
CMG Digital is known for setting the industry tone when it comes to sustainability. Historically, the agency standardised recycling long before it became compulsory. Now, it is leading the way once more and focussing on standardising its approach to digital sustainability.
As global-to-local experts, CMG Digital puts a strong focus on maximising content life through reuse, recycling and repurposing to reduce the digital waste of its clients.
This focus is allowing CMG Digital to spread its message, educate and upskilling clients and brands in digital sustainability as well as digital inclusivity.
CMG Digital hopes that its position as a leader in its field will enable it to set the tone and encourage other agencies to follow its example. The agency is a powerhouse in its industry, credited with delivering over 50,000 projects, working with more than 200 global brands and delivering to over 100 markets worldwide. Since 2001 it has been the digital custodian of some of the world’s most valuable brands across the globe, and today leading digital deployment for multinational corporations such as P&G, GSK, Novartis, ConvaTec, Cloetta, Edgewell and Rimac.
CMG Digital believes its relaunch will help it better achieve its overall goal of empowering brands to scale their global message to the local level with consistency and pace.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005009/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
